Krystal Biotech, Inc. (NASDAQ:KRYS) Stock Has Consensus Price Target of $375.00

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have been assigned a consensus recommendation of “Moderate Buy” from the fourteen analysts that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $375.00.

A number of analysts have weighed in on KRYS shares. Citigroup reduced their price target on Krystal Biotech from $416.00 to $412.00 and set a “buy” rating for the company in a research report on Tuesday, November 3rd. Jefferies Financial Group reissued a “buy” rating and set a $474.00 price objective on shares of Krystal Biotech in a report on Monday, July 13th. TD Cowen cut their price objective on Krystal Biotech from $403.00 to $380.00 and set a “buy” rating on the stock in a research note on Tuesday, November 3rd. The Goldman Sachs Group assumed coverage on Krystal Biotech in a report on Thursday, September 24th. They issued a “buy” rating and a $441.00 target price for the company. Finally, Royal Bank Of Canada decreased their target price on Krystal Biotech from $400.00 to $375.00 and set an “outperform” rating for the company in a research report on Tuesday, November 3rd.

Krystal Biotech Trading Up 0.7%

Krystal Biotech stock opened at $303.06 on Friday. The company has a market capitalization of $8.98 billion, a P/E ratio of 42.18 and a beta of 0.56. The firm’s fifty day simple moving average is $331.51 and its 200-day simple moving average is $309.20. Krystal Biotech has a 1-year low of $197.13 and a 1-year high of $382.54.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, November 2nd. The company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.79 by $0.26. The business had revenue of $127.34 million during the quarter, compared to analyst estimates of $125.77 million. Krystal Biotech had a net margin of 47.91% and a return on equity of 17.02%. On average, equities research analysts predict that Krystal Biotech will post 7.74 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $359.32, for a total value of $8,983,000.00. Following the transaction, the insider owned 1,302,145 shares of the company’s stock, valued at $467,886,741.40. This trade represents a 1.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino Rossi sold 25,000 shares of the business’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the completion of the sale, the director owned 50,000 shares of the company’s stock, valued at $16,456,000. The trade was a 33.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 13.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. BlackRock Inc. bought a new stake in Krystal Biotech during the second quarter valued at about $1,554,113,000. William Blair Investment Management LLC acquired a new position in shares of Krystal Biotech during the 2nd quarter worth about $211,909,000. Jupiter Topco LLC acquired a new position in shares of Krystal Biotech during the 2nd quarter worth about $95,387,000. Bank of America Corp DE bought a new stake in Krystal Biotech during the 2nd quarter valued at approximately $95,308,000. Finally, Bank of New York Mellon Corp bought a new stake in Krystal Biotech during the 2nd quarter valued at approximately $60,809,000. Institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc is a biotechnology company that develops genetic medicines for people with serious diseases. Founded in 2016 and headquartered in Pittsburgh, Pennsylvania, the company focuses on treatments that deliver functional genes to patients’ cells.

Its commercial product, Vyjuvek (beremagene geperpavec-svdt), is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder. The treatment is designed to help cells produce collagen VII, a protein that supports the skin’s structure.